1703 - 基于 BAW 的智能体人工智能.pdf

1、Orlando,FLOctober 69IBM TechXchange 2025Session 1703Transforming Eli Lillys Clinical Trial Operations with workflow-driven AI agentsEric Ducos Salient Process,CTOManaging PartnerAgentic AI Meets Workflow AutomationGreg S GrafEli Lilly,Sr.Director Enterprise AutomationAgendaIntro-Eli Lilly&Salient Pr

2、ocessTechnology Overview BAW AI AgentsCTI Implementation&ChallengesDemo481317IBM TechXchange|2025 IBM Corporation2Future Outlook19Agenda0102030405Intro-Eli Lilly&Salient ProcessTechnology Overview-BAW AI AgentsCTI Implementation&ChallengesDemoFuture OutlookIBM TechXchange|2025 IBM CorporationLilly&S

3、alient CollaborationAggressive Lilly AI Research&Investment ProgramSignificant volume and momentum for Gen AI for automation and efficiencies.Pervasive corporate-driven priority.Clinical Trials Insurance(CTI)2.0Existing workflow solution with obvious agentic AI applicationsWhat ifWhat would a workfl

4、ow-driven CTI solution look like with Agentic AI for low-level work planning and execution?4IBM TechXchange|2025 IBM CorporationOverviewCollaborative InnovationEli Lilly leverages and collaborates on Salient Process Agentic AI with Business Automation Workflow to solve complex challenges(internation

5、al drug trials).Aligned Operational OutcomesSeamless co-existence between workflow and AI agents delivers improved efficiency,compliance,and investment alignment with the IBM automation ecosystem.Blueprint for Workflow-driven AI AdoptionProject serves as a model for IBM clients to integrate AI agent

6、s within existing workflow infrastructure&investment.5IBM TechXchange|2025 IBM CorporationWhy AI Agents for BAW?AI Agent Process Management Capabilitiesnot great compared to world-class leading workflow management platform like BAW.AI Agent to Production Workflow Gap Too WideTechnology stack complex